| Nome |
# |
|
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review, file e27ce42b-89b5-2581-e053-d805fe0acbaa
|
1.180
|
|
Current insights in obstetric antiphospholipid syndrome, file e27ce42f-01af-2581-e053-d805fe0acbaa
|
628
|
|
Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review, file e27ce42b-d333-2581-e053-d805fe0acbaa
|
527
|
|
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence, file e27ce42b-a1cf-2581-e053-d805fe0acbaa
|
487
|
|
Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review, file e27ce42b-648e-2581-e053-d805fe0acbaa
|
484
|
|
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome, file e27ce42b-8f7d-2581-e053-d805fe0acbaa
|
433
|
|
The risk of ischaemic stroke in primary APS patients: a prospective study, file e27ce42d-8fd1-2581-e053-d805fe0acbaa
|
431
|
|
Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin autoantibodies in antiphospholipid syndrome: A multicenter study, file e27ce42e-ad43-2581-e053-d805fe0acbaa
|
403
|
|
Prevalence and Thrombotic Risk Assessment of Anti-beta(2) Glycoprotein I Domain I Antibodies: A Systematic Review, file e27ce42d-ede1-2581-e053-d805fe0acbaa
|
389
|
|
Pregnancy outcomes in mixed connective tissue disease: a multicentre study, file e27ce42e-e06c-2581-e053-d805fe0acbaa
|
387
|
|
The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction, file e27ce42b-a1cb-2581-e053-d805fe0acbaa
|
378
|
|
Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials, file e27ce42b-a1d5-2581-e053-d805fe0acbaa
|
354
|
|
Infodemiology of systemic lupus erythematous using Google Trends, file e27ce42e-e76a-2581-e053-d805fe0acbaa
|
352
|
|
Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?, file e27ce42e-090e-2581-e053-d805fe0acbaa
|
336
|
|
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management, file e27ce42e-ded1-2581-e053-d805fe0acbaa
|
299
|
|
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents, file e27ce42d-9fdb-2581-e053-d805fe0acbaa
|
274
|
|
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study, file e27ce42d-ae45-2581-e053-d805fe0acbaa
|
251
|
|
Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS, file e27ce42e-d865-2581-e053-d805fe0acbaa
|
246
|
|
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab, file e27ce42d-a247-2581-e053-d805fe0acbaa
|
227
|
|
Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring, file e27ce42e-d349-2581-e053-d805fe0acbaa
|
225
|
|
Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score, file e27ce430-70db-2581-e053-d805fe0acbaa
|
206
|
|
Thrombotic antiphospholipid syndrome, file e27ce42f-1ad5-2581-e053-d805fe0acbaa
|
195
|
|
Antiphospholipid antibodies negativization: Time for testing for non-criteria aPL?, file e27ce42f-53ce-2581-e053-d805fe0acbaa
|
190
|
|
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome, file e27ce430-41be-2581-e053-d805fe0acbaa
|
189
|
|
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort, file e27ce42f-1ada-2581-e053-d805fe0acbaa
|
166
|
|
Filling the gap in antiphospholipid syndrome diagnosis: a patient's story, file e27ce42f-98df-2581-e053-d805fe0acbaa
|
160
|
|
Antiphospholipid antibodies: crossroads between autoimmunity and infections?, file e27ce42b-7a39-2581-e053-d805fe0acbaa
|
158
|
|
Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay, file e27ce429-e533-2581-e053-d805fe0acbaa
|
156
|
|
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: A pooled analysis, file e27ce42d-a36c-2581-e053-d805fe0acbaa
|
122
|
|
The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience, file e27ce42e-cbae-2581-e053-d805fe0acbaa
|
122
|
|
Recent advances in the management of systemic lupus erythematosus, file e27ce42d-9afd-2581-e053-d805fe0acbaa
|
117
|
|
Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion, file e27ce42e-8dbe-2581-e053-d805fe0acbaa
|
107
|
|
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies, file e27ce433-fd7a-2581-e053-d805fe0acbaa
|
105
|
|
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris, file e27ce42d-cf4b-2581-e053-d805fe0acbaa
|
101
|
|
The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study, file e27ce42d-eeb6-2581-e053-d805fe0acbaa
|
97
|
|
Tailoring tofacitinib oral therapy in rheumatoid arthritis: The TuTORApp—a usability study, file e27ce42f-c97d-2581-e053-d805fe0acbaa
|
87
|
|
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study, file e27ce42d-8fd3-2581-e053-d805fe0acbaa
|
85
|
|
Hydroxychloroquine reduces IL-6 and pro-thrombotic status, file e27ce42f-a8c0-2581-e053-d805fe0acbaa
|
76
|
|
Antiphospholipid Antibodies and Infection: Non Nova Sed Nove, file e27ce432-91f6-2581-e053-d805fe0acbaa
|
68
|
|
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome, file e27ce42e-74ec-2581-e053-d805fe0acbaa
|
67
|
|
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease, file e27ce433-dd16-2581-e053-d805fe0acbaa
|
61
|
|
IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients, file e27ce42f-d66e-2581-e053-d805fe0acbaa
|
60
|
|
Genetic factors in antiphospholipid syndrome: Preliminary experience with whole exome sequencing, file e27ce431-2352-2581-e053-d805fe0acbaa
|
60
|
|
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss, file e27ce435-1ce5-2581-e053-d805fe0acbaa
|
58
|
|
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome, file e27ce42d-b61e-2581-e053-d805fe0acbaa
|
53
|
|
Treatment of antiphospholipid syndrome, file e27ce432-1608-2581-e053-d805fe0acbaa
|
52
|
|
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study, file e27ce432-694d-2581-e053-d805fe0acbaa
|
46
|
|
Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease, file e27ce433-d04c-2581-e053-d805fe0acbaa
|
46
|
|
Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation, file e27ce432-5686-2581-e053-d805fe0acbaa
|
39
|
|
Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients, file 78634fc4-f863-42cb-941c-b51d282574eb
|
36
|
|
Renal Fibrosis in Lupus Nephritis, file 9828c83a-6f2f-455a-b6be-745d6b61e0bb
|
30
|
|
Recent advances in the management of systemic lupus erythematosus, file e27ce42d-9afe-2581-e053-d805fe0acbaa
|
30
|
|
Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients, file 259e65c5-fea8-4658-a776-4ce0ec1b0bd0
|
27
|
|
Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review, file e27ce42f-b076-2581-e053-d805fe0acbaa
|
27
|
|
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets, file e27ce432-6e57-2581-e053-d805fe0acbaa
|
26
|
|
Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/ prothrombin antibodies, file e27ce432-1464-2581-e053-d805fe0acbaa
|
19
|
|
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS), file e27ce435-a6ee-2581-e053-d805fe0acbaa
|
18
|
|
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis, file 4082c612-f982-4e7a-ad97-915d7ebf580e
|
16
|
|
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome, file d4bffba0-2eb3-419b-99b6-8d55cfb7774c
|
16
|
|
Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"?, file e27ce42d-a36a-2581-e053-d805fe0acbaa
|
13
|
|
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology, file e27ce435-a6f3-2581-e053-d805fe0acbaa
|
13
|
|
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome, file e27ce432-53d2-2581-e053-d805fe0acbaa
|
12
|
|
Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet’s Disease: A Systematic Review, file 69057f5f-e46a-47c3-95d1-dcc7539eca80
|
8
|
|
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies, file e27ce432-6f3b-2581-e053-d805fe0acbaa
|
8
|
|
Serum Biomarkers of Renal Fibrosis: A Systematic Review, file 5660b69d-5bec-4605-9466-ac6c8675cf63
|
7
|
|
New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing, file ceaacf1d-feb0-44f5-a815-5a23ba446a3f
|
7
|
|
Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients, file e27ce42d-aba6-2581-e053-d805fe0acbaa
|
6
|
|
Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort, file e27ce42d-ec86-2581-e053-d805fe0acbaa
|
6
|
|
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers, file f4db0fda-37fa-4a60-aa26-7d39464375e0
|
6
|
|
Chasing the Zebra: a case of membranous-like Glomerulopathy with SSA/RO52 deposits and no overt connective tissue disease, file 2a0a659a-1148-4220-8ace-f4283d88a1cf
|
5
|
|
Renal involvement as a unique manifestation of hemophagocytic syndrome, file 78f67454-24d4-46d6-acd4-ce946bc8bc73
|
5
|
|
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS), file be2e8244-8758-413e-8655-134c2cd382e0
|
5
|
|
Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients, file e27ce430-06a0-2581-e053-d805fe0acbaa
|
5
|
|
Pregnancy outcomes in mixed connective tissue disease: a multicentre study, file e27ce432-500a-2581-e053-d805fe0acbaa
|
5
|
|
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience, file f2f69fe9-88f1-483b-bab2-50108e2ff0ba
|
5
|
|
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies, file 3d716316-26db-498f-8d9b-1046ce9a89cb
|
4
|
|
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients, file e27ce42f-b109-2581-e053-d805fe0acbaa
|
4
|
|
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19, file e27ce42f-fe97-2581-e053-d805fe0acbaa
|
4
|
|
Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies, file 721ca36d-f3ad-4d4c-af18-86b538988da4
|
3
|
|
Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab, file 82d96280-fa92-4b83-9add-eaa99353f275
|
3
|
|
Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study, file e27ce42f-caff-2581-e053-d805fe0acbaa
|
3
|
|
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss, file e27ce432-2f18-2581-e053-d805fe0acbaa
|
3
|
|
Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients, file e27ce432-3a47-2581-e053-d805fe0acbaa
|
3
|
|
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach, file 3ff16da9-a8fa-48b2-a9f6-910475801b59
|
2
|
|
Identifying subsets of patients with undifferentiated connective tissue disease: Results from a prospective, real-world experience using particle-based multi-analyte technology, file 69eb8cbd-82d8-4130-8baf-cc4c5a68d9cc
|
2
|
|
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App, file 8652c547-b14b-4867-8748-cbeae989f13d
|
2
|
|
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol, file bbc707de-c8d7-46d2-8baf-665234b527a0
|
2
|
|
Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology., file e27ce42d-9af8-2581-e053-d805fe0acbaa
|
2
|
|
Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients, file e27ce42d-9afa-2581-e053-d805fe0acbaa
|
2
|
|
Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"?, file e27ce42d-b624-2581-e053-d805fe0acbaa
|
2
|
|
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study, file e27ce42d-c60e-2581-e053-d805fe0acbaa
|
2
|
|
Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials, file e27ce42d-cd78-2581-e053-d805fe0acbaa
|
2
|
|
Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review, file e27ce42d-d2f0-2581-e053-d805fe0acbaa
|
2
|
|
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study, file e27ce42d-e0bb-2581-e053-d805fe0acbaa
|
2
|
|
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris, file e27ce42d-e82d-2581-e053-d805fe0acbaa
|
2
|
|
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome, file e27ce42d-e889-2581-e053-d805fe0acbaa
|
2
|
|
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome, file e27ce42f-b070-2581-e053-d805fe0acbaa
|
2
|
|
Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis, file e27ce430-d55b-2581-e053-d805fe0acbaa
|
2
|
|
The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities, file e27ce431-ec8d-2581-e053-d805fe0acbaa
|
2
|
|
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS), file e27ce432-5f01-2581-e053-d805fe0acbaa
|
2
|
| Totale |
11.762 |